Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023

Verrica Pharmaceuticals Inc.

Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.
Collaboration revenue of $9.0M in FY 2022, down from $12.0M in FY 2021.
Cash and equivalents $34.3M at Dec 31, 2022; raised $32.5M gross in Feb 2023 secondary offering.
FDA assigned PDUFA date of July 23, 2023 for VP-102 NDA for molluscum contagiosum.
VP-315 Phase 2 Part 2 dosing expected to begin in Q2 2023 for basal cell carcinoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Verrica Pharmaceuticals Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-060702

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.